Xenova Biomedix Report issue

For profit Phase 1 Phase 3
Founded: Reading United Kingdom (1990)
Status: Acquired by Celtic Pharma Development Services (2005)

Organization Overview

First Clinical Trial
2002
NCT00052624
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

transforming growth factor(alpha)-pseudomonas aeruginosa exotoxin (1 trial)

Drugs in Phase 1 Trials (1)

transferrin-crm107 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 1)

Central Nervous System Neoplasms (Phase 1)

Glioblastoma (Phase 3)

Nervous System Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2